A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
NCT ID: NCT01408602
Last Updated: 2014-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
300 participants
INTERVENTIONAL
2011-11-30
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
NCT00847613
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
NCT01651936
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
NCT01569152
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
NCT00928512
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Treatment 1, Placebo: 2 tablets taken tid
* Treatment 2, MRC375: 1 tablet of 75 mg tetracycline HCL plus 1 matching placebo tablet taken tid. Total daily dose = 225 mg.
* Treatment 3, MRC375: 2 tablets of 75 mg tetracycline HCL taken tid. Total daily dose = 450 mg.
Study medication should be taken within 30 minutes of a meal or light snack (either before or after).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MRC375 75 mg
MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
MRC375
MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Placebo
Placebo
Matching Placebo
Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRC375
MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
Matching Placebo
Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Is diagnosed with moderate to severe adult onset RA \> = 6 months duration, as defined by the 1987 ACR classification criteria
3. Has moderate to severe RA as defined by:
* ≥4 tender joints/painful (28 joint count) at screening
* ≥4 swollen joints (28 joint count) at screening
4. Has a Health Assessment Questionnaire (HAQ) of \>0
5. Has a physician global assessment (Likert scale) of \>0
6. Has a patient global assessment of pain (Likert scale) of \>0
7. Has a patient assessment of pain (Likert scale) of \>0
8. Has stable doses of the following allowable medications during the study, if applicable:
* Stable dose of NSAIDs or other analgesics for at least 2 weeks prior to administration of study drug at regulatory approved doses
* Stable dose of methotrexate 7.5 mg to 25 mg/day once weekly for at least 6 weeks prior to administration of study drug (no changes in dosing regimen for 4 weeks prior to screening)
* Stable dose of hydroxychloroquine either monotherapy or in combination with methotrexate 8 weeks prior to administration of study drug
9. Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea
10. If female of childbearing potential, must agree to use one of the following acceptable birth control methods:
* Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to screening, hysterectomy, or bilateral oophorectomy);
* Intrauterine device (IUD) in place for at least 3 months prior to first dose of study drug;
* Abstinence (not having sexual intercourse);
* Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion;
* Stable hormonal contraceptive for at least 3 months prior to study and through study completion
11. If female of childbearing potential, has a negative serum hCG pregnancy test at screening
12. Is able to swallow whole tablets of orally administered medication
13. Is able to understand and provide signed informed consent.
Exclusion Criteria
2. Has a secondary type of arthritis (eg, osteoarthritis) that would interfere with study evaluations
3. Has taken the following drugs within the timeframe specified below:
* Infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab) - Within 12 weeks prior to the administration of study drug;
* Rituximab - Within 12 months prior to the administration of study drug;
* Disease-modifying antirheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above including but not limited to: sulfasalazine, gold, leflunomide, penicillamine, dapsone, azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil - Within 12 weeks prior to the administration of study drug;
* Any steroids (glucocorticoids); glucocorticoids must be discontinued for at least 4 weeks prior to administration of study drug. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to administration of study drug.
* Note: Use of probiotics is allowed and is NOT an exclusion criterion.
4. Has a uncontrolled symptoms of fibromyalgia with sufficient symptoms requiring treatment (NOTE: patients on a stable dose of treatment for symptoms of fibromyalgia ≥ 4 weeks will be allowed in the study.)
5. Has a history of allergic reaction to tetracycline or other related drugs
6. Had major surgery or trauma within 28 days prior to screening
7. Is concurrently using minocycline or doxycycline (washout of 4 weeks required before the administration of study drug)
8. Patients who are on chronic antibiotics or who are on antibiotics for GI infections (such as Clostridium difficile)
9. Has clinically significant ECG abnormalities
10. Has any clinically significant abnormal laboratory test results found during medical screening including: AST or ALT \> 2 x upper limit of normal or serum creatinine \> 2.0 mg/dL
11. Has clinically significant history or presence of any gastrointestinal pathology (eg, chronic diarrhea, inflammatory bowel disease, acute diverticulitis), irritable bowel syndrome, unresolved gastrointestinal symptoms (eg. diarrhea, vomiting, symptoms of acute diverticulitis), liver or kidney disease, gastric bypass, gastric stapling, use of Lap-Band®, or other conditions known to or which might interfere with the absorption, distribution, metabolism, or excretion of the drug
12. Has any historical or active neurological, endocrine, cardiovascular, pulmonary, hematological, psychiatric, or metabolic disease that is considered clinically significant by the Investigator
13. Has known history of HIV, hepatitis B or C (patients that have positive hepatitis B serology due to prior vaccination will be allowed in the study)
14. Has an active malignancy of any type or history of malignancy. Patients who have a history of a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma (ie. non melanoma skin cancer)and/or localized carcinoma in situ of the cervix are eligible. Patients with a history of other malignancies that have been treated and who have no evidence of recurrence for at least 5 years before study enrollment are also eligible.
15. Has difficulty swallowing tablets
16. Is ACR Functional Class IV (limited ability to perform usual self-care, vocational, and avocational activities)
17. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)
18. Has clinically significant mental illness (to be determined by the Investigator)
19. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements. Has exposure to any investigational agent within 30 days prior to study entry.
20. Was previously enrolled in this study
21. Has recent history of bacterial intestinal tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)
22. Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Camargo Pharmaceutical Services
INDUSTRY
Clin Data Services
UNKNOWN
Harrison Clinical Research
INDUSTRY
BARC Global Central Laboratory
UNKNOWN
Bilcare Global Clinical Supplies
UNKNOWN
Molecular Research Center, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile Diagnostic Center Rheumatology
Mobile, Alabama, United States
Valerius Medical Group
Long Beach, California, United States
Trial Concierge/Pacific Clinical Studies
Los Alamitos, California, United States
Axis Clinical Trials
Los Angeles, California, United States
Riverside Clinical Research
Edgewater, Florida, United States
Global Clinical Professionals
Miami, Florida, United States
The Arthritis Center
Palm Harbor, Florida, United States
Lakeview Medical Research
Summerfield, Florida, United States
Analan Clinical Research
Lenexa, Kansas, United States
Trial Concierge
Owensboro, Kentucky, United States
Quality Clinical Research, Inc.
Omaha, Nebraska, United States
Advanced BioMedical Research of America
Las Vegas, Nevada, United States
Arthritis Center of Reno
Reno, Nevada, United States
PMG Research of Salisbury
Salisbury, North Carolina, United States
Providence Health Partners
Dayton, Ohio, United States
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio, United States
The Center for Excellence in Aging and Geriatric Health
Williamsburg, Virginia, United States
Apex Clinical Research
Kennewick, Washington, United States
South Puget Sound Clinical Research Center
Olympia, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRC2011-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.